---
schema_version: "secwatch.filing_event.v1"
accession: "0001510964-22-000065"
form_type: "8-K"
ticker: "CVSI"
cik: "0001510964"
company_name: "CV Sciences, Inc."
filed_at: "2022-08-15T23:59:59+00:00"
generated_at: "2026-06-23T23:49:08.052824+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# CV Sciences Q2 2022 revenue falls 19% to $4.1M; gross margin drops to 30.7%

## Summary
- Revenue $4.1M down from $5.1M YoY; units sold decreased 5%.
- Gross margin 30.7% vs 44.7% in Q2 2021, hurt by product mix and higher discounts.
- Operating loss narrowed to $2.3M from $3.5M; adj. EBITDA loss $1.8M (vs $2.4M).
- Cash balance $1.1M at quarter end; OPEX reduced 38.2% YoY.
- Regained top hemp extract brand in natural retail per SPINS; strategic review ongoing.

## SEC filing metadata
- accession: 0001510964-22-000065
- form_type: 8-K
- ticker: CVSI
- cik: 0001510964
- company_name: CV Sciences, Inc.
- filed_at: 2022-08-15T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1510964/000151096422000065/0001510964-22-000065-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1510964/000151096422000065/cvsi-20220815.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001510964-22-000065
- JSON: https://secwatch.observer/filing/0001510964-22-000065.json
- Plain text: https://secwatch.observer/filing/0001510964-22-000065.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.